Dr. Marc Hedrick
and to you, QX. Thank Erica, afternoon. Good welcome our
Plus time I’m the Accounting As have for me to joining Officer, Therapeutics and Controller Erica Marc Ms. CEO said, I’m and first happy our Hedrick, today Corporate President Smith. Principal Desiree of and
results Plus honestly first history. reinvested a third under indeed short extremely most the three the Company. It and quarter quarter pleased a a the in important Therapeutics is the for In months, identically was clinical milestone for itself operating for XXXX stage reported company. Plus oncology Plus which Therapeutics us report to perhaps as the I’m Company's quarter Therapeutics,
a of Let me hit you. for few those highlights
and for cash BARDA from offering and Human First of public Health balance in in on long-term our the to both adding million $XX U.S. achieved work our a viability million the directed all, million including of sheet we $X.X $XX series of Services reimbursement contract. Department approximately actions a a through payment
Texas where an had lower from timely of California calls That Institute of active Provision a Texas by forward also to a that move billion, cap doubled $X issuances Company of preexisting the measure the CPRIT. state a to bond of moved Cancer and and coincided the headquarters lower voters it approval we and Research operations. was value ballot that XXXX look center November with facility cost, to we Texas Second,
second U.S. of largest be nation's now company, believe CPRIT partner the there public relocated. is that research after to have cancer we opportunities We CPRIT funder with greater the that as a will Texas-centric Government.
a sweeping development business Finally, our focus we and change model. structural to made
As very order maximize our speed capital virtualized efficiency, development for as model our real previously employees and described, quality. estate capital only not to footprint we essential we the base specifically importantly, deliberately in to full-time and returned saw efficiency, core, but for
use providers agile intend now experts core small We to to service the team. third best supplement our and party
structure lean we've With our long-term that it. base future margin these that growth. dramatic and moves drive platform It's cost architected viability to scale for a and sustainable built design supported we intend is to maximize able to
financial cost quarter the growth. development a and to In with strength, for strategy, emerges maximize third summary, structure Therapeutics from viability the and opportunity Plus focused long-term
Now, proceed path. at the strategically in utilizing a regulatory large part as designed to we opportunities such Orphan accelerate to FDA pace, drug XXX(b)(X) commercialization intend brisk by
and including drug the drug current of drug specifically in as formulation is well core redesign drug formulation, Plus Therapeutics scale and complex in manufacturing expertise as nanoparticle up.
focusing effectively also cost Phase and clinical moved rapidly are can that We be X. on and stage late preclinical drugs specifically through early
and can asset, can core that confident married benefits in So, therapeutics extraordinary tremendous growing provide we're shareholders with our we patients a pipeline, produce line. to to
to making forth it forward going portfolio guide set relates medical and Plus commercial our criteria. as a to has straight decision forward As three development,
or medical must an address drug need. First, unmet every Therapeutics substantially Plus underserved
at new there have extensive million technology information effectively. and safety least indications. should more known that more market must for And Second, and tried there ingredients the it true deliver taking we efficacy finally, of with using those believe and pharmaceutical to active safely the combine $XXX new by and selected is that addressable
asset in and small need complex API Now, address discuss entity I Phase asset, three reformulated albumin-stabilized proprietary squarely development lung a is clinically that. possibly to the widely clinical is that quite lead is More There pegylated is an recognized a pivot just let mentioned. agent stage all our checks which boxes ready also new DocePLUS on X based like DocePLUS a me liposomal unmet cancer docetaxel. specifically chemical to over docetaxel. other. cell DocePLUS proven
cancer, The version U.S. this of $XXX million drug in was opportunity earlier namely version sufficiency granted with a a sales small of leading improved an intended year represents the with for to year lung completed orphan be a appropriateness communications our substantially annually. the a FDA peak oncology them market package, which U.S. XXX(b)(X) studies DocePLUS, principle, pathways of designation something drug X.X, is cell non-clinical estimated drug. a the TAXOTERE. of in accepted by for Sanofi the as This
lethal lung ranging or Phase cancer rates the filing feedback survival The X small that response to five-year path illustrates considered with strongly to generally trial. as for drug. potential approval endpoint cancer for of from FDA's primary pivotal accelerated subtype most a cell forward very for plan XX%, the this the suitability positive relative a believe objective lung X% rate We
of conventional discussion I to won't previous meaningfully reiterate we our be docetaxel. investor believe why superior could calls DocePLUS
to or the do of but believe similar we we're who's the DocePLUS course is while happy profile efficacy share better safety with potential than conventional this has any that docetaxel. simultaneously -- improve However, to that investor providing
over in to U.S. terms pre-medication specifically those the reactions reiterate X data, attacks. to as offer the indicated morbidity, well the safety competed of escalation DocePLUS and of docetaxel of in perhaps approved within efficacy dose limits XX clinical in of To pretreated dosage Tween of evidence injection one conventional heavily API patients, hypersensitivity the of to lower of XX, related even avoidance avoidance resistant docetaxel DocePLUS as dose study and the trial of Phase phase our patients terms advantages the FDA that appears
cancer. two our days cell initiation seeking the beyond of develop small we trial protocol, to establishment are liposomal for the the to and treatment. result, for submit to of disease clinical intend as potential on intend of a treatment after following use we sufficient indication, XX we a near our we that On execute of cell disease docetaxel cell phase own first small partners platinum small But progressed line. of this platinum In indication forms other with the DocePLUS to patients least scope. plan actively lung cancer As program, term, of in are the indications first sensitive DocePLUS on patients, lung expand formulation accelerate development tend to to we line who sensitive at cancer of
in The with liposomal secondary with expand our corporate active final drug the objectives. our as we or we pipeline are generic in number of of doxorubicin, Europe. this in DocePLUS a Regarding acquiring are version new opportunities discussions asset, parties Caelyx reviewing point, other consistent interested in to a licensing
now, And very pleased to it a Ms. Corporate I'm review. our over Desiree? to Desiree Smith, for turn financial Controller
